Literature DB >> 19467855

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

William E Tidyman1, Katherine A Rauen.   

Abstract

The Ras/mitogen activated protein kinase (MAPK) pathway is essential in the regulation of the cell cycle, differentiation, growth and cell senescence, all of which are critical to normal development. It is therefore not surprising that its dysregulation has profound effects on development. A class of developmental syndromes, the 'RASopathies', is caused by germline mutations in genes that encode protein components of the Ras/MAPK pathway. The vast majority of these mutations result in increased signal transduction down the Ras/MAPK pathway, but usually to a lesser extent than somatic mutations associated with oncogenesis. Each syndrome exhibits unique phenotypic features, however, since they all cause dysregulation of the Ras/MAPK pathway, there are numerous overlapping phenotypic features between the syndromes, including characteristic facial features, cardiac defects, cutaneous abnormalities, neurocognitive delay and a predisposition to malignancies. Here we review the clinical and underlying molecular basis for each of these syndromes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467855      PMCID: PMC2743116          DOI: 10.1016/j.gde.2009.04.001

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  53 in total

1.  Fgf signalling controls the dorsoventral patterning of the zebrafish embryo.

Authors:  Maximilian Fürthauer; Jeanne Van Celst; Christine Thisse; Bernard Thisse
Journal:  Development       Date:  2004-05-19       Impact factor: 6.868

2.  Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts.

Authors:  R M Cawthon; P O'Connell; A M Buchberg; D Viskochil; R B Weiss; M Culver; J Stevens; N A Jenkins; N G Copeland; R White
Journal:  Genomics       Date:  1990-08       Impact factor: 5.736

3.  Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

Authors:  J B Gibbs; I S Sigal; M Poe; E M Scolnick
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

4.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

5.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients.

Authors:  M R Wallace; D A Marchuk; L B Andersen; R Letcher; H M Odeh; A M Saulino; J W Fountain; A Brereton; J Nicholson; A L Mitchell
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

6.  K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

Authors:  L Johnson; D Greenbaum; K Cichowski; K Mercer; E Murphy; E Schmitt; R T Bronson; H Umanoff; W Edelmann; R Kucherlapati; T Jacks
Journal:  Genes Dev       Date:  1997-10-01       Impact factor: 11.361

Review 7.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

8.  Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations.

Authors:  Iiro Eerola; Laurence M Boon; John B Mulliken; Patricia E Burrows; Anne Dompmartin; Shoji Watanabe; Romain Vanwijck; Miikka Vikkula
Journal:  Am J Hum Genet       Date:  2003-11-24       Impact factor: 11.025

9.  Induction of Xenopus oocyte meiotic maturation by MAP kinase.

Authors:  O Haccard; A Lewellyn; R S Hartley; E Erikson; J L Maller
Journal:  Dev Biol       Date:  1995-04       Impact factor: 3.582

10.  Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.

Authors:  Corina Anastasaki; Anne L Estep; Richard Marais; Katherine A Rauen; E Elizabeth Patton
Journal:  Hum Mol Genet       Date:  2009-04-17       Impact factor: 6.150

View more
  268 in total

1.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

2.  Two hydrophobic residues can determine the specificity of mitogen-activated protein kinase docking interactions.

Authors:  A Jane Bardwell; Lee Bardwell
Journal:  J Biol Chem       Date:  2015-09-14       Impact factor: 5.157

Review 3.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

Review 4.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

5.  Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.

Authors:  Masako Yaoita; Tetsuya Niihori; Seiji Mizuno; Nobuhiko Okamoto; Shion Hayashi; Atsushi Watanabe; Masato Yokozawa; Hiroshi Suzumura; Akihiko Nakahara; Yusuke Nakano; Tatsunori Hokosaki; Ayumi Ohmori; Hirofumi Sawada; Ohsuke Migita; Aya Mima; Pablo Lapunzina; Fernando Santos-Simarro; Sixto García-Miñaúr; Tsutomu Ogata; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2015-12-29       Impact factor: 4.132

6.  Atypical phenotypes associated with pathogenic CHD7 variants and a proposal for broadening CHARGE syndrome clinical diagnostic criteria.

Authors:  Caitlin L Hale; Adrienne N Niederriter; Glenn E Green; Donna M Martin
Journal:  Am J Med Genet A       Date:  2015-11-21       Impact factor: 2.802

7.  ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.

Authors:  Yuan Wang; Edward Kim; Xiaojing Wang; Bennett G Novitch; Kazuaki Yoshikawa; Long-Sheng Chang; Yuan Zhu
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

8.  Kir2.1 Interaction with Stk38 Promotes Invasion and Metastasis of Human Gastric Cancer by Enhancing MEKK2-MEK1/2-ERK1/2 Signaling.

Authors:  Cheng-Dong Ji; Yan-Xia Wang; Dong-Fang Xiang; Qiang Liu; Zhi-Hua Zhou; Feng Qian; Lang Yang; Yong Ren; Wei Cui; Sen-Lin Xu; Xi-Long Zhao; Xia Zhang; Yan Wang; Peng Zhang; Ji-Ming Wang; You-Hong Cui; Xiu-Wu Bian
Journal:  Cancer Res       Date:  2018-03-16       Impact factor: 12.701

Review 9.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

Review 10.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.